期刊
BIOMEDICINES
卷 11, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines11092581
关键词
neurodegeneration; osteopenia; osteoporosis; sarcopenia; spinal cord injury
Osteoporosis and sarcopenia are major concerns for individuals with SCI, affecting their quality of life. Recent research has improved our understanding of the mechanisms and risk factors for musculoskeletal loss after SCI, and offers pharmacological and non-pharmacological therapies to reduce or eliminate neurogenic bone loss following SCI.
Osteoporosis is a common skeletal disorder which can severely limit one's ability to complete daily tasks due to the increased risk of bone fractures, reducing quality of life. Spinal cord injury (SCI) can also result in osteoporosis and sarcopenia. Most individuals experience sarcopenia and osteoporosis due to advancing age; however, individuals with SCI experience more rapid and debilitating levels of muscle and bone loss due to neurogenic factors, musculoskeletal disuse, and cellular/molecular events. Thus, preserving and maintaining bone mass after SCI is crucial to decreasing the risk of fragility and fracture in vulnerable SCI populations. Recent studies have provided an improved understanding of the pathophysiology and risk factors related to musculoskeletal loss after SCI. Pharmacological and non-pharmacological therapies have also provided for the reduction in or elimination of neurogenic bone loss after SCI. This review article will discuss the pathophysiology and risk factors of muscle and bone loss after SCI, including the mechanisms that may lead to muscle and bone loss after SCI. This review will also focus on current and future pharmacological and non-pharmacological therapies for reducing or eliminating neurogenic bone loss following SCI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据